The engagement of PD-L1 with one of its receptors, PD-1, leads to the negative regulation of CD3-mediated lymphocyte proliferation [27] and the deletion of activated lymphocytic T cells in the tumor microenvironment (TME) [19]. The gene discussed is PDCD1; the disease is neoplasm.